INTRESO
20.6.2024 08:01:34 CEST | Business Wire | Press release
International Treatment Solutions (INTRESO) Group has written to the EU Commission’s Standing Committee on Biocidal Products to highlight the availability of safe, effective and environmentally sustainable alternatives to sulfuryl fluoride, ahead of a 21 June meeting which will consider a ban of the chemical for the preservation treatment of wood [PT8], and as an insecticide and acaricide for the control of insects and arachnids [PT18].
On 21 June, representatives from EU Member States will vote on a proposal to ban the use of sulfuryl fluoride, an extremely harmful synthetic greenhouse gas with a global warming potential more than 4500 times that of carbon dioxide, for these fumigation purposes. In what amounts to an effective ban, the EU is considering withdrawing approvals for the continued biocidal use of sulfuryl fluoride, due to a lack of data on the potential risks to human health posed by the chemical.
INTRESO Group produces BLUEFUME™, a highly effective and environmentally sustainable drop-in replacement for sulfuryl fluoride. BLUEFUME™ is the latest iteration of a tried and tested chemical, HCN, successfully used around the world for decades. INTRESO Group’s product is fully approved in numerous markets including in the EU, UK, Australia, New Zealand, Malaysia, Morocco and South Africa. Most recently, it has been put through rigorous testing and approval processes in Australia in 2023, with subsequent regulatory approval demonstrating impressive results against the latest standards.
Effective and economical, BLUEFUME™ breaks down into naturally occurring substances, meaning it also has a far lower environmental footprint than sulfuryl fluoride.
Besides being a Biocidal Product, sulfuryl fluoride is also a Plant Protection Product for the treatment of tree logs exported from the EU. In which case, additionally, INTRESO Group’s proprietary product, Ethanedinitrile (EDN™), is a highly effective and environmentally sustainable drop-in replacement for sulfuryl fluoride and has already been approved for the fumigation of timber and wood products in countries including Australia, New Zealand, South Korea, Malaysia, Uruguay, South Africa and Turkey. EDN was also successfully used over successive years in the Czech Republic under emergency use authorization during their recent bark beetle outbreak. This demonstrates that other major agricultural exporters have moved faster than the EU in approving alternative chemicals which adhere to stringent modern safety and environmental standards.
Commenting on the potential new restrictions on the use of sulfuryl fluoride in the EU, Kade McConville, Executive Director of INTRESO Group said:
“The claims that there is no available and highly effective alternative to sulfuryl fluoride for biocidal and plant protection use are simply not true. Our products, including EDN™ and BLUEFUME, are drop-in replacements that have been shown to be efficient under a wider set of climatic conditions than sulfuryl fluoride.
With increasing evidence as to the harms to human health and the planet resulting from sulfuryl fluoride, it is vitally important that EU decision-makers consider and understand the fact that alternative solutions are readily available for use in European fumigation, and that whilst sulfuryl fluoride is a tool, it is not the only tool in the toolbox.
Ahead of this pivotal vote, I have written to the Commission to make clear that our innovative, environmentally sustainable solutions already provide an effective alternative to sulfuryl fluoride in forward-thinking countries with some of the strictest biosecurity standards, including Australia and New Zealand.”
Background
- Fumigation is essential to protect against risks of invasive pests from international trade in raw commodities, with Europe facing unprecedented levels of bark beetle breakouts in conifer forests1.
- Sulfuryl fluoride, the most widely used fumigant in the EU, has a Global Warming Potential (GWP) more than 4500 times that of carbon dioxide.
- Use of sulfuryl fluoride is increasingly globally.
- Negotiations on the EU’s F-Gas Regulation, adopted in March 2024, resulted in new monitoring and recapture requirements and considered a total ban.
- EDNTM has a GWP over 4400x lower than sulfuryl fluoride.
- For more information on INTRESO: www.intreso.com
| ____________________ | |
1 |
https://foresteurope.org/bark-beetle-outbreaks-in-forests-a-pan-european-view/ |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240619174501/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Amazfit Announces the T-Rex Ultra 2: a Titanium GPS Watch Engineered for the Extreme19.2.2026 13:00:00 CET | Press release
With preloaded global maps, intelligent route tools, and weeks-long battery life, the T-Rex Ultra 2 is made for those who seek boundaries only to push beyond Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the T-Rex Ultra 2, the latest and most advanced member of its rugged T-Rex lineup. As part of the T-Rex family, the T-Rex Ultra 2 is built for uncertainty—designed to remain reliable in conditions where plans, environments, and outcomes are never fully defined. Purpose-built for extreme environments, the T-Rex Ultra 2 combines premium materials, enhanced navigation capabilities, and extended battery life to support athletes and explorers tackling long, complex routes where preparation and reliability matter most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219679075/en/ Amazfit Announces the T-Rex Ultra 2: a Titanium GPS Watch Engineered for the Extreme “With the T-Rex Ultra 2, we
YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency19.2.2026 12:00:00 CET | Press release
Single dose of YOLT-202 led to rapid, robust and dose-dependent increases in AAT levels to normal rangeSingle dose of YOLT-202 was well tolerated with a favorable safety profile YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene editing therapies, today announced positive interim data from an investigator-initiated trial (IIT) of YOLT-202, the Company’s investigational in vivo base editing therapy, for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) that demonstrated positive safety and tolerability as well as meaningful increases in AAT levels in evaluated patients treated with the 35 mg and 45 mg dose levels. “These interim findings mark an exciting and important milestone for YolTech and for patients living with severe AATD. The rapid, robust, and dose‑dependent increases in functional AAT levels observed in this study—particularly among individuals with the PiZZ genotype—underscore the transformative potential of in vivo base editing as
Infobip Recognized as RCS for Business Leader by Juniper Research19.2.2026 11:15:00 CET | Press release
Recognition comes as Infobip celebrates its 20th anniversary Global cloud communications platform Infobip has been named the number one Established Leader in the Juniper Research RCS for Business 2026 Leaderboard. The analyst firm scored Infobip as the top vendor out of 17 because of its superior capability and capacity, enhanced product and position and significant market presence. Juniper Research scores vendors on a range of factors including but not limited to their geographical reach, depth of partnerships, RCS value-added services, notable RCS deployments, and innovation. According to Juniper Research, Infobip stands out for its wide network of mobile operator connections for RCS for Business and its extensive geographic reach, including being the first provider to launch RCS messaging across all major US telecom carriers. Brands such as Virgin Atlantic are using Infobip’s RCS solutions to deliver interactive, conversational messaging that drives stronger customer engagement. Mol
Serviceplan Group Deploys Creative AI Across Global Operations in Partnership With Luma AI19.2.2026 11:00:00 CET | Press release
Serviceplan Group becomes the first of the world’s largest agency groups to standardize AI for creative work across professional workflows at scale, strengthening productivity and long-term competitiveness. Serviceplan Group today announced a strategic partnership with Luma AI to deploy AI for creative work across the agency group’s global operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219346568/en/ Serviceplan Group today announced a strategic partnership with Luma AI to deploy AI for creative work across the agency group’s global operations. Shown here (L-R) Alex Schill, Global Chief Creative Officer of Serviceplan Group, Jason Day, Head of EMEA for Luma AI, Amit Jain, Co-Founder and CEO of Luma AI, and Florian Haller, CEO of Serviceplan Group. Under the agreement, Luma AI will serve as Serviceplan Group’s AI technology partner, embedding AI for creative work into professional workflows spanning strategy, cr
GekkoVet and Royal Canin Enter Latin America with Mexico Launch, Opening a New Continent in their Global Partnership19.2.2026 10:59:00 CET | Press release
GekkoVet, the Finnish leader in AI-powered clinical decision support for veterinarians, and Royal Canin, a global pioneer in pet health through nutrition, announce the launch of their strategic collaboration in Mexico. This marks the first national rollout of their partnership in Latin America, expanding the initiative that began earlier this year with successful deployments in Asia. Royal Canin Mexico is equipping veterinary teams with GekkoVet’s intelligent platform, which provides real-time diagnostic assistance, treatment recommendations, and drug information. The collaboration aims to enhance clinical efficiency, improve patient outcomes, and support veterinarians with evidence-based tools that integrate seamlessly into daily practice. “This launch in Mexico is a major step forward—not just regionally, but globally,” said Johanna Majamaa, DVM and co-founder of GekkoVet. “After strong momentum in Asia, entering Latin America opens a new chapter in our mission to empower veterinaria
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
